embecta - EMBC
EMBC
Close Chg Chg %
11.86 0.21 1.77%
Closed Market
12.07
+0.21 (1.77%)
Volume: 367.46K
Last Updated:
Dec 30, 2025, 4:00 PM EDT
Company Overview: embecta - EMBC
EMBC Key Data
| Open $11.80 | Day Range 11.76 - 12.15 |
| 52 Week Range 9.20 - 21.23 | Market Cap $702.25M |
| Shares Outstanding 59.21M | Public Float 54.53M |
| Beta 1.06 | Rev. Per Employee N/A |
| P/E Ratio 7.42 | EPS $1.63 |
| Yield 499.58% | Dividend $0.15 |
| EX-DIVIDEND DATE Dec 5, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 793.00K |
EMBC Performance
| 1 Week | 0.50% | ||
| 1 Month | -5.37% | ||
| 3 Months | -15.71% | ||
| 1 Year | -41.55% | ||
| 5 Years | N/A |
EMBC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About embecta - EMBC
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
EMBC At a Glance
Embecta Corp.
300 Kimball Drive
Parsippany, New Jersey 07417-07054
| Phone | 1-862-401-0000 | Revenue | 1.08B | |
| Industry | Medical Specialties | Net Income | 95.40M | |
| Sector | Health Technology | Employees | 1,850 | |
| Fiscal Year-end | 09 / 2026 | |||
| View SEC Filings |
EMBC Valuation
| P/E Current | 7.417 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 8.714 |
| Price to Sales Ratio | 0.769 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 4.34 |
| Enterprise Value to EBITDA | 5.389 |
| Enterprise Value to Sales | 1.898 |
| Total Debt to Enterprise Value | 0.706 |
EMBC Efficiency
| Revenue/Employee | 584,000.00 |
| Income Per Employee | 51,567.568 |
| Receivables Turnover | 7.256 |
| Total Asset Turnover | 0.899 |
EMBC Liquidity
| Current Ratio | 2.415 |
| Quick Ratio | 1.732 |
| Cash Ratio | 0.874 |
EMBC Profitability
| Gross Margin | 62.893 |
| Operating Margin | 30.479 |
| Pretax Margin | 12.616 |
| Net Margin | 8.83 |
| Return on Assets | 7.941 |
| Return on Equity | N/A |
| Return on Total Capital | 11.973 |
| Return on Invested Capital | 11.591 |
EMBC Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 181.652 |
| Total Debt to Total Assets | 129.544 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 179.167 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Embecta - EMBC
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.13B | 1.12B | 1.12B | 1.08B | |
Sales Growth
| -3.05% | -0.77% | +0.21% | -3.80% | |
Cost of Goods Sold (COGS) incl D&A
| 354.60M | 370.90M | 394.20M | 400.90M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 31.70M | 32.70M | 42.50M | 51.10M | |
Depreciation
| 31.00M | 31.50M | 35.10M | 39.60M | |
Amortization of Intangibles
| 700.00K | 1.20M | 1.10M | 1.10M | |
COGS Growth
| -2.85% | +4.60% | +6.28% | +1.70% | |
Gross Income
| 774.90M | 749.90M | 728.90M | 679.50M | |
Gross Income Growth
| -3.14% | -3.23% | -2.80% | -6.78% | |
Gross Profit Margin
| +68.61% | +66.91% | +64.90% | +62.89% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 359.80M | 426.50M | 443.90M | 352.90M | |
Research & Development
| 65.00M | 85.20M | 78.80M | 21.50M | |
Other SG&A
| 294.80M | 341.30M | 365.10M | 331.40M | |
SGA Growth
| +18.75% | +18.54% | +4.08% | -20.50% | |
Other Operating Expense
| 37.00M | 93.80M | 110.80M | (2.70M) | |
Unusual Expense
| 68.50M | 8.10M | 7.40M | 87.20M | |
EBIT after Unusual Expense
| 309.60M | 221.50M | 166.80M | 242.10M | |
Non Operating Income/Expense
| (6.80M) | (8.80M) | (10.30M) | 1.50M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 46.20M | 107.00M | 112.30M | 107.30M | |
Interest Expense Growth
| - | +131.60% | +4.95% | -4.45% | |
Gross Interest Expense
| 46.20M | 107.00M | 112.30M | 107.30M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 256.60M | 105.70M | 44.20M | 136.30M | |
Pretax Income Growth
| -48.16% | -58.81% | -58.18% | +208.37% | |
Pretax Margin
| +22.72% | +9.43% | +3.94% | +12.62% | |
Income Tax
| 33.00M | 35.30M | (34.10M) | 40.90M | |
Income Tax - Current - Domestic
| 23.80M | 1.80M | 25.40M | 2.50M | |
Income Tax - Current - Foreign
| 35.70M | 19.20M | 11.10M | 20.80M | |
Income Tax - Deferred - Domestic
| (35.70M) | 6.60M | (48.70M) | 7.30M | |
Income Tax - Deferred - Foreign
| 9.20M | 7.70M | (21.90M) | 10.30M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 223.60M | 70.40M | 78.30M | 95.40M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 223.60M | 70.40M | 78.30M | 95.40M | |
Net Income Growth
| -46.12% | -68.52% | +11.22% | +21.84% | |
Net Margin Growth
| +19.80% | +6.28% | +6.97% | +8.83% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 223.60M | 70.40M | 78.30M | 95.40M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 223.60M | 70.40M | 78.30M | 95.40M | |
EPS (Basic)
| 3.919 | 1.2297 | 1.3575 | 1.6361 | |
EPS (Basic) Growth
| -46.36% | -68.62% | +10.39% | +20.52% | |
Basic Shares Outstanding
| 57.06M | 57.25M | 57.68M | 58.31M | |
EPS (Diluted)
| 3.919 | 1.2189 | 1.3424 | 1.6193 | |
EPS (Diluted) Growth
| -46.36% | -68.90% | +10.13% | +20.63% | |
Diluted Shares Outstanding
| 57.06M | 57.76M | 58.33M | 58.91M | |
EBITDA
| 409.80M | 262.30M | 216.70M | 380.40M | |
EBITDA Growth
| -22.68% | -35.99% | -17.38% | +75.54% | |
EBITDA Margin
| +36.28% | +23.40% | +19.29% | +35.21% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 19.50 | |
| Number of Ratings | 4 | Current Quarters Estimate | 0.668 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 2.888 | |
| Last Quarter’s Earnings | 0.672 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.95 | Next Fiscal Year Estimate | 2.935 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 4 | 4 |
| Mean Estimate | 0.67 | 0.86 | 2.89 | 2.93 |
| High Estimates | 0.70 | 0.98 | 2.93 | 3.04 |
| Low Estimate | 0.63 | 0.79 | 2.82 | 2.88 |
| Coefficient of Variance | 4.79 | 9.89 | 1.59 | 2.59 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 1 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 2 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Embecta - EMBC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Embecta - EMBC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 9, 2025 | Shaun Curtis SVP, Global Manuf./Sup. Chain | 59,061 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $12 per share | 708,732.00 |
| Apr 9, 2025 | Devdatt Kurdikar President and CEO; Director | 499,582 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $12 per share | 5,994,984.00 |
| Apr 9, 2025 | Jeff Z. Mann SVP, GC, Head Corp. Dev., Secy | 139,439 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $12 per share | 1,673,268.00 |
| Apr 9, 2025 | Jacob Elguicze SVP and CFO | 168,599 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $12 per share | 2,023,188.00 |
| Feb 26, 2025 | David F. Melcher Director | 76,681 | Open market or private purchase of non-derivative security Non-derivative transaction at $13.67 per share | 1,048,229.27 |
| Feb 17, 2025 | Christopher R. Reidy Director | 45,284 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Karen Naomi Prange Director | 39,743 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Robert J. Hombach Director | 39,749 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Milton Mayo Morris Director | 39,233 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Milton Mayo Morris Director | 36,133 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $16.38 per share | 591,858.54 |
| Feb 17, 2025 | David J. Albritton Director | 39,743 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Claire Pomeroy Director | 41,289 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Carrie L. Anderson Director | 39,743 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |